Skip to content

Satisfactory analgesia with minimal emesis after video-assisted thoracic surgery: a randomized controlled trial comparing patient-controlled intravenous analgesia with oxycodone, hydromorphone, and sufentanil

Satisfactory analgesia with minimal emesis after video-assisted thoracic surgery: a randomized controlled trial comparing patient-controlled intravenous analgesia with oxycodone, hydromorphone, and sufentanil

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100045614
Enrollment
Unknown
Registered
2021-04-19
Start date
2021-04-21
Completion date
Unknown
Last updated
2021-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patient-controlled intravenous analgesia after video-assisted thoracic surgery

Interventions

Oxycodone group (O) :Oxycodone
Hydromorphone group (H):Hydromorphone
Sufentanil group (S) :Sufentanil

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years; 2. ASA: I-III; 3. Elective thoracoscopic lung resection; 4. The informed consent form has been signed.

Exclusion criteria

Exclusion criteria: 1. Participants who are unable to cooperate with the study for any reason, or in the opinion of the investigator, they are not suitable for this trial; 2. Patients who are allergic to drugs used in the research process, allergic to sulfa drugs, and are using floxacin antibiotics; 3. Long-term use of analgesics; 4. Patients with confirmed sleep apnea or chronic obstructive airway disease or bronchial asthma; 5. Patients with ischemic heart disease or pulmonary heart disease, peripheral arterial or cerebrovascular disease; 6. Patients with a history of gastrointestinal bleeding or perforation after the application of non-steroidal anti-inflammatory drugs, patients with active peptic ulcer or gastrointestinal bleeding, or patients with inflammatory bowel disease; 7. Patients during pregnancy or lactation; 8. Patients with moderate to severe hepatic impairment (Child-Pugh score B or C) or severe renal impairment (creatinine clearance rate <10ml/min); 9. Patients taking monoamine oxidase inhibitors or within 2 weeks after stopping; 10. Patients who refuse to use intravenous analgesia pumps.

Design outcomes

Primary

MeasureTime frame
Proportion of satisfactory analgesia and lightest vomiting when coughing within 3 days after surgery;

Secondary

MeasureTime frame
Proportion of satisfactory analgesia and lightest vomiting at rest within 3 days after surgery;The dosage of analgesic pump in 3 days after operation;Patient satisfaction with analgesia;Duration of postoperative hospital stay;Quality QOR-15 recovered 3 days after operation;Other adverse reactions of analgesic drugs;

Countries

China

Contacts

Public ContactYu Hai

West China Hospital, Sichuan University

706603748@qq.com+86 18980601548

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 14, 2026